levetiracetam extended release / Generic mfg. - LARVOL DELTA

ELITE: Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma (clinicaltrials.gov) - P2 | N=140 | Not yet recruiting | Sponsor: Tianjin Medical University General Hospital

New P2 trial • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CA9 • HIF1A

Retrospective study on canine idiopathic epilepsy treatment in primary care practices in the United States. (PubMed, Front Vet Sci) - "Phenobarbital (34.9%) and levetiracetam (31.3%) were the most prescribed first-line-ASDs, followed by zonisamide (22.9%) and potassium bromide (11.1%)...Extended-release levetiracetam was used in 97.4% of cases; the median dose was 29.7 mg/kg (IQR 24.1-34.6 mg/kg) PO, prescribed every 12 h in 87.7% of dogs...Prescribing practices generally aligned with the ACVIM guidelines, suggesting good implementation of this knowledge in one of the largest US primary care providers. The variability in levetiracetam and potassium bromide dosing highlights the need for updated evidence-based dosing guidelines, while education on the value of therapeutic drug monitoring could support veterinary and pet-owner's decision making in the management of IE."

Journal • Retrospective data • CNS Disorders • Epilepsy

Evaluation of Efficacy and Review of Side Effect Profile in Epilepsy Patients Treated with Extended-Release Levetiracetam. (PubMed, Pak J Med Sci) - "Transitioning from LEV IR to LEV ER may offer clinically meaningful advantages in selected patient populations. Nevertheless, further prospective studies with larger cohorts are warranted to confirm these findings."

Adverse events • Journal • CNS Disorders • Epilepsy • Psychiatry

Dissolution Characteristics of Split and Crushed Levetiracetam Extended-Release Tablets in Comparison With Immediate-Release Formulation. (PubMed, J Vet Pharmacol Ther) - "Conversely, crushing LEV-XR tablets may be useful for rapid drug release in cluster seizure protocols. Future pharmacokinetic studies are needed to confirm if these in vitro results correlate with in vivo performance for both maintenance and emergency seizure management in dogs."

Journal • CNS Disorders • Epilepsy

The Single-Dose Pharmacokinetics of a Compounded Levetiracetam Formulation and Bioequivalence to a Commercial Formulation in Healthy Dogs. (PubMed, J Vet Pharmacol Ther) - "PO-COMP may improve medication adherence and seizure control relative to immediate-release LEV, which requires three times daily dosing. Efficacy studies of PO-COMP are warranted."

Journal • PK/PD data • CNS Disorders • Epilepsy

Duration of Prophylactic Levetiracetam After Surgery for Brain Tumor: A Prospective Randomized Trial. (PubMed, Neurosurgery) - "The use of prophylactic levetiracetam did not result in significant neurotoxicity or depression when given for either 1 week or 6 weeks. The incidence of seizure after craniotomy for tumor resection is low regardless of duration of therapy."

Journal • Brain Cancer • CNS Disorders • Depression • Epilepsy • Oncology • Psychiatry • Solid Tumor

1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients (clinicaltrials.gov) - P4; N=82; Active, not recruiting; Sponsor: University of Florida; Trial completion date: Mar 2021 ➔ Mar 2022; Trial primary completion date: Mar 2021 ➔ Mar 2022

Clinical • Trial completion date • Trial primary completion date • Brain Cancer • CNS Disorders • Epilepsy • Oncology • Solid Tumor

Alzheimer's trial will use drug made for epilepsy (Oxford Mail) - "Researchers in Oxford have launched a six-month trial to see whether an anti-epilepsy drug can help to treat memory loss in patients with Alzheimer's disease....Tests using mice have shown that the anti-epileptic drug Levetiracetam can reduce abnormal brainwave activity and reverse memory deficits."

Clinical